CN
122-72-5
应用筛选条件
关键词:'122-72-5'
显示 1-30 共 94 条结果 关于 "122-72-5" 范围 技术文档
Quality Control Range Sheet- HST-110 and HST-210
pg/mL
Control 2 122 – 254 pg/mL Control 2 172 – 357 pg/mL
IL-1β Control 1 17 – 34 pg/mL TNFα Control 1
MultiScreen Filter Plates with Ultracel®-10 Membrane
45 39 32 26 28 30 38 44
BSA 125 128 122 136 115 126 124 120
Buffer 132 142 176 140 136 138 131 123
Cyto c 122 131 124 119 118 123 124 117
FBS 79 70 57 43 42
Data Sheet - M0820
-
391 (1995).
5. Roth, M.P., et al., Genomics, 28, 241-250 (1995).
6. Li, G., et al., Brain Pathol., 12, 463-471 (2002).
7. Johns, T.G., and Bernard, C.C., J. Neurochem., 72,
1-9 (1999).
Data Sheet - M0695
386-
391 (1995).
5. Roth, M.P., et al., Genomics, 28, 241-250 (1995).
6. Li, G., et al., Brain Pathol., 12, 463-471 (2002).
7. Johns, T.G., and Bernard, C.C., J. Neurochem., 72,
1-9 (1999).
Data Sheet - C9733
augments c-Jun activity
and stimulates phosphorylation of its activation
domain. Nature, 351, 122-127 (1991).
2. Smeal, T., et al., Oncogenic and transcriptional
cooperation with Ha-Ras requires
Quality Control Range Sheet- A60MG-104 and A60MG-204
Units
MCSF Control1 1483 - 3080 pg/ml
Control 2 7157 - 14865 pg/ml
MIG/CXCL9 Control1 122 – 289 pg/ml
Control 2 761 - 1580 pg/ml
Stem Cell and Specialty Cell Culture Product Guide
................................ 72, 122
CD11b .................................................................................................................. 122
CD14 ........................
Examination of Non-Specifically Bound Proteins and Peptides Following Depletion of Twenty High Abundance Proteins from Human Plasma
83 2 170 4 50 1 122 3 241 8 434 13
IPI00783987 Complement C3 precursor 716 18 74 2 804 16 77 2 886 19 205 6 686 16 54 1 49 1 105 3 1411 37
Data Sheet - E7032 - Lot SLBB5961V
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
Data Sheet - E7032 - Lot 061M0757
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
Data Sheet - E7032
Activity of Typical Lot:
122–165 nmole/min/mg
Procedure
Preparation Instructions
Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM
glycerol 2-phosphate, 25 mM MgCl2, 5 mM EGTA, and
2 mM EDTA. Just
Data Sheet - E7032 - Lot 021M0609
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
Data Sheet - E7032 - Lot 041M0961
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
Data Sheet - E7032 - Lot 051M0813
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
Data Sheet - E7032 - Lot 019K0645
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
Data Sheet - E7032 - Lot 021M0606
glycerol.
Molecular mass: ∼62 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 122–165 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not
ISODIS 2998 (1)
rights reserved 3
5.1 Basic materials
See ISO 8261 | IDF 122 and ISO/TS 11133-1
5.2 Diluent(s)
See ISO 8261 | IDF 122.
The following recommendations are made.
Spare parts for Mobius® FlexReady Solution with Smart Flexware® Assemblies For Chromatography and TFF
Multi-Use Flowmeter
72
Applicable for
FT002 + WFT002 + FT002M
or FT004 + WFT004 + FT004M
68
72
68
27
5. Flowmeter
XMO3 Single-Use Flowmeter
76
Applicable
XP725 Antibody Number-Lot Number 071M4826
18 19 20 41 42 43 44 65 66 67 68 89 90 91 92
1.6 21 22 23 24 45 46 47 48 69 70 71 72 93 94 95 96
2.1 97 98 99 100 121 122 123 124 145
Data Sheet - P1431
Acad. Sci. USA,
72(1), 64-68 (1975).
40. Jones, H. et al., Biochim. Biophys. Acta, 714(1),
152-156 (1982).
41. Stull, J.T., in Molecular Aspects of Cellular
Regulation, Volume 5: Calmodulin (P.
Product Information Sheet - SE120097
myoglobin
determinations in the assessment of acute
myocardial infarction. Eur. Heart Journal, 3:122,
(1982).
4. Cairns, J.P. et.al., Usefulness of serial
determinations of myoglobin and creatine
The Effective Use of Protein Kinase Inhibitors
107 122 18 6 7 0 104 103 27 52 41 97 99 82 94 62 114 50 107 113
101 91 98 104 87 65 36 31 89 88 62 86 61 97 77 108 100 95 83
Product Information Sheet - P2277
5948-
5955 (1982).
40. Cohen, P., Mol. Aspects Cell. Regul., 5, 123-144
(1988).
41. Stull, J., Mol. Aspects Cell. Regul., 5, 91-122
(1988).
42. Klee, C., Methods Enzymol., 102, 227-244 (1983).
Data Sheet - C7594
Practical
Approach, IRL Press, NY, p. 67-70 (1994).
9. Fortin, A. et al., Biochem. Cell Biol., 72(5-6),
239-243 (1994).
Trizma is a registered trademark of Sigma-Aldrich Co.
Microfil User Guide
WG0 72
0.8 µm MCE white gridded 72/pk MIAA WG0 72
0.8 µm MCE black gridded 72/pk MIAA BG0 72
1.2 µm MCE white gridded 72/pk MIRA WG0 72
0.45 µm Durapore white plain 72/pk MIHV WP0 72
PF05801 efi_RevA.p65
lkaline Phosphatase Procedure. No. 85
Fast Violet B _____________ ____________
LAPA Mean ± 1 SD 96±44 72±50
LAPA Range 52–140 22–122
ALKALINE
PHOSPHATASE
(Procedure No. 85)
1-E
The Effective Use of Protein Kinase Inhibitors
107 122 18 6 7 0 104 103 27 52 41 97 99 82 94 62 114 50 107 113
101 91 98 104 87 65 36 31 89 88 62 86 61 97 77 108 100 95 83
Evaluation of Methods for Removal of Highly Abundant Human Plasma Proteins
10 7 123 13
vitamin D-binding protein 17 9 122 25
Apolipoprotein B 3 2 309 121
Transthyretin (prealbumin) 7 4 5 3
Prothrombin (Coagulation factor II) 3 3 72 25
Serum Amyloid P Component 6 4 1 1
Vitronectin
Data Sheet - P8375
and liver of C57BL/6J mice".
Technischen Universität München, Dr. rer. nat.
dissertation, p. 122 (2014).
35. Borges, Alexandre Filipe Guerreiro, "The
grapevine defences: Walking towards the ‘
Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease
1983).
36. Ling, N., et al., Biochem. Biophys. Res. Commun., 122, 1218-1224 (1984).
37. Esch, F., et al., Biochem. Biophys. Res. Commun., 122, 899-905 (1984).
38. Patthy, M., et al., Proc. Natl. Acad. Sci
1/4